DHEA-S Should Not Be Routinely Used for Depression or SLE
Based on the highest quality evidence, DHEA supplementation is not recommended for treating depression or systemic lupus erythematosus in clinical practice. The evidence shows either no benefit or inconsistent results that do not justify routine use.
For Depression
The 2014 Endocrine Society Clinical Practice Guideline explicitly states there is insufficient data to support the routine use of DHEA in women without adrenal insufficiency 1. While one small open-label study from 1997 showed improvements in depression ratings and memory in 6 patients with low baseline DHEA levels 2, this preliminary finding has not been validated in larger, controlled trials.
Key Evidence Against Use:
- The guideline notes that most DHEA studies on cognition have been too brief to provide meaningful results 1
- The most rigorous study (50 mg/d DHEA for 1 year) reported no benefit on comprehensive cognitive testing 1
- A Cochrane Review concluded no evidence that DHEA therapy improves cognitive performance in people over 50 without dementia 1
Limited Exception:
DHEA may have small benefits in adrenal insufficiency specifically, where a meta-analysis showed possible small improvements in health-related quality of life and depression 1. However, even in this population, effects on anxiety or sexual well-being were absent 1.
For Systemic Lupus Erythematosus
DHEA is not recommended for SLE treatment. The 2024 EULAR guidelines for SLE management make no mention of DHEA as a therapeutic option 3, effectively excluding it from evidence-based treatment algorithms.
Definitive Evidence Against Use:
A 2010 randomized, double-blind, placebo-controlled trial (n=60) in women with quiescent SLE found:
- No differential effect of 200 mg daily DHEA versus placebo on fatigue, depressive mood, mental well-being, or physical functioning 4
- Both groups improved equally (placebo effect)
- The belief that DHEA had been used was a stronger predictor of improvement than actual DHEA use (p=0.04) 4
- The authors explicitly state: "DHEA treatment is not recommended in unselected female patients with quiescent SLE" 4
Supporting Evidence:
The 2007 Cochrane systematic review of 7 RCTs (842 participants) concluded 5:
- DHEA had little clinical effect on disease activity in mild/moderate SLE
- Only modest improvement in patient global assessment (11.5% improvement)
- Doubled risk of androgenic adverse effects like acne (RR 2.2; 95% CI 1.65-2.83)
- Long-term outcomes and safety remain unstudied
A 2012 study found that low DHEAS levels in SLE were not related to fatigue - in fact, patients with low DHEAS not using prednisone reported less fatigue than those with normal levels 6, contradicting the rationale for supplementation.
Clinical Bottom Line
Do not prescribe DHEA for depression or SLE. The evidence consistently shows no clinically meaningful benefit, while exposing patients to androgenic side effects (particularly acne). The 2024 EULAR SLE guidelines prioritize anifrolumab and belimumab as evidence-based biologics for extrarenal disease 3, representing the actual therapeutic advances in SLE management.
Common Pitfall to Avoid:
Do not be swayed by patients' low DHEA levels alone - these correlate poorly with symptoms and do not predict treatment response. The placebo effect is substantial in both conditions, as demonstrated by the SLE trial where belief in receiving DHEA was more predictive of improvement than actual drug use 4.